GlassScriptPhysician profile
Ilan Aharoni
NPI 1851423701
$56,258.64
in general payments reported to CMS, 2019-2025
22 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2021: $90.18 · 2022: $224 · 2023: $1,069 · 2024: $25K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Travel and Lodging: $4,203 · Food and Beverage: $4,178 · Consulting Fee: $3,835 · Education: $21.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,575.00 |
| Travel and Lodging | $4,203.47 |
| Food and Beverage | $4,178.47 |
| Consulting Fee | $3,835.00 |
| Education | $21.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25,685.95 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Pfizer INC. | $25,480.06 | 2022-2025 | |
| Celltrion USA INC. | $3,942.97 | 2024-2025 | Vegzelma, Zymfentra |
| Takeda Pharmaceuticals U.S.A., INC. | $257.25 | 2023-2025 | Entyvio |
| Janssen Biotech, INC. | $134.88 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $125.07 | 2022 | |
| Medical Device Business Services, INC. | $116.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.78 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Phathom Pharmaceuticals, INC. | $87.48 | 2024 | Voquezna |
| Janssen Scientific Affairs, LLC | $73.76 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $40.58 | 2025 | Omvoh |
| Genzyme Corporation | $39.07 | 2022-2023 | |
| Boston Scientific Corporation | $38.22 | 2023 | |
| Axonics, INC. | $33.68 | 2021 | |
| Novo Nordisk INC | $24.13 | 2025 | Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.51 | 2023 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $21.23 | 2023 | |
| Evoke Pharma, INC. | $15.61 | 2023 | Gimoti |
| Covidien LP | $14.91 | 2019 | |
| Erbe USA INC | $10.00 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilan Aharoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.